ResMed (RMD) valuation
ResMed P/E ratio history
ResMed trades at 20.9 times its earnings over the last twelve months and 18.6 times the earnings analysts expect over the next twelve. At its last 10 fiscal year ends its P/E ranged from 18.7 (year to Jun 2026) to 76.1 (year to Jun 2021), with a median of 37.7.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Jun 30, 2026 | $194.88 | $10.43 | 18.7 | 16.3 |
| Jun 30, 2025 | $258.00 | $9.51 | 27.1 | 25.0 |
| Jun 30, 2024 | $191.42 | $6.92 | 27.7 | 22.8 |
| Jun 30, 2023 | $218.50 | $6.09 | 35.9 | 30.5 |
| Jun 30, 2022 | $209.63 | $5.30 | 39.6 | 32.9 |
| Jun 30, 2021 | $246.52 | $3.24 | 76.1 | — |
| Jun 30, 2020 | $192.00 | $4.27 | 45.0 | — |
| Jun 30, 2019 | $122.03 | $2.80 | 43.6 | — |
| Jun 30, 2018 | $103.58 | $2.19 | 47.3 | — |
| Jun 30, 2017 | $77.87 | $2.40 | 32.5 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
ResMed valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| ResMedRMD | $33.4B | 20.9 | 18.6 | 5.9 |
| GE HealthCareGEHC | $34.6B | 16.2 | 14.3 | 1.6 |
| DexcomDXCM | $31.1B | 32.4 | 27.3 | 6.1 |
| Idexx LaboratoriesIDXX | $43.5B | 38.7 | 34.9 | 9.6 |
| SterisSTE | $22.2B | 27.8 | 19.8 | 3.7 |
| Edwards LifesciencesEW | $53.0B | 52.9 | 28.9 | 8.1 |
| Becton DickinsonBDX | $54.5B | 74.5 | 15.1 | 2.6 |
| Zimmer BiometZBH | $18.3B | 22.9 | 10.8 | 2.2 |
| Boston ScientificBSX | $62.4B | 17.0 | 13.2 | 3.0 |
| Peer median | 30.1 | 17.4 | 3.3 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: RMD financials · RMD returns
No forecast, no recommendation. This page describes ResMed from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.